Eicher Motors, the maker of Royal Enfield, posted a 12% rise in net profit for the March quarter of FY26. ...More

Eicher Motors, the maker of Royal Enfield, posted a 12% rise in net profit for the March quarter of FY26. The company's revenue also saw a 16% increase. Royal Enfield achieved its highest quarterly sales and surpassed one million units annually for the second year. VE Commercial Vehicles also reported strong sales growth. ...Less

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from ...More

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26. ...Less

Sun Pharmaceutical Industries reported a net profit of Rs 3,117.95 crore for Q2 FY26, a 2.6% year-on-year ...More

Sun Pharmaceutical Industries reported a net profit of Rs 3,117.95 crore for Q2 FY26, a 2.6% year-on-year increase. Revenue from operations grew 8.6% to Rs 14,405.22 crore, with U.S. Innovative Medicines sales surpassing Generics for the first time. The company's R&D investment stood at 5.4% of sales. ...Less

The earnings for interest, tax, depreciation and ammortisation (EBITDA) rose 7.5% to Rs. 3179.4 crore in ...More

The earnings for interest, tax, depreciation and ammortisation (EBITDA) rose 7.5% to Rs. 3179.4 crore in Q2, and EBITDA margins declined 90 basis points YoY to 26.1%. India formulation sales rose 11.1% YoY to Rs. 3843 crore in Q2FY24. India accounts for 32% of Sun Pharma sales ...Less

The pharma major's profit was higher than ET Now poll estimate of Rs 2,040 crore. However, revenue was be ...More

The pharma major's profit was higher than ET Now poll estimate of Rs 2,040 crore. However, revenue was below the expected figure of Rs 11,090 crore. ...Less

Sun Pharmaceutical Q2 FY25 Results: Sun Pharma reported a 28% increase in consolidated net profit for Q2, ...More

Sun Pharmaceutical Q2 FY25 Results: Sun Pharma reported a 28% increase in consolidated net profit for Q2, reaching Rs 3,040 crore, up from Rs 2,375 crore last year. Revenue rose 9% YoY to Rs 13,291 crore, surpassing market estimates. EBITDA grew 24% YoY to Rs 3,939 crore, with a margin of 29.6%. Formulation sales in India increased 11% YoY to Rs 4,265 crore, representing 32% of total sales. ...Less

Revenue from operations is likely to jump 10% year-on-year, according to the average estimate of four bro ...More

Revenue from operations is likely to jump 10% year-on-year, according to the average estimate of four brokerages. Meanwhile, net profit for the quarter is projected to rise by up to 25% YoY. The pharma major will report its September quarter results on Monday, October 28. ...Less

The operational performance, however, will be hit by higher research and development costs, input prices, ...More

The operational performance, however, will be hit by higher research and development costs, input prices, and continued erosion in prices in the US generics market. Sun Pharma’s US-based subsidiary Taro Pharmaceutical Industries, which released Q2 earnings last week, reported an operating loss of $6.8 million against a profit of $24.4 million a year ago, primarily due to pricing pressure in the generics drug market. ...Less

Operating profit, calculated as earnings before interest, taxes, depreciation, and amortization (EBITDA), ...More

Operating profit, calculated as earnings before interest, taxes, depreciation, and amortization (EBITDA), for the quarter, rose nearly 8% on year to Rs 3,179.30 crore, but operating margin contracted by 91 basis points to 26.08%. Total expenses in the quarter rose to Rs 9,695 crore, from Rs 8,625 crore a year ago. ...Less

The drug maker had reported a loss of Rs 269.60 crore in the corresponding quarter last year. ...More

The drug maker had reported a loss of Rs 269.60 crore in the corresponding quarter last year. ...Less

Sales in the US were $339 million for the quarter, flat over the same period last year. ...More

Sales in the US were $339 million for the quarter, flat over the same period last year. ...Less

Sun Pharma is expected to report modest Q2 FY26 earnings growth, with PAT likely up 2% YoY and revenue ri ...More

Sun Pharma is expected to report modest Q2 FY26 earnings growth, with PAT likely up 2% YoY and revenue rising 7%. Analysts cite Leqselvi launch costs, weak Taro performance, and high R&D spend as margin drags, even as domestic and specialty segments continue to drive overall growth. ...Less

Sun Pharma’s net sales for the quarter rose 16.10 per cent to Rs 7,949.19 crore. ...More

Sun Pharma’s net sales for the quarter rose 16.10 per cent to Rs 7,949.19 crore. ...Less

Sun Pharma will be in focus after reporting a Q2 FY26 net profit of Rs 3,117.95 crore, up 2.6% YoY, with ...More

Sun Pharma will be in focus after reporting a Q2 FY26 net profit of Rs 3,117.95 crore, up 2.6% YoY, with revenue rising 8.6% to Rs 14,405 crore. Innovative Medicines drove growth, surpassing U.S. generics for the first time. EBITDA rose 14.9% with strong margins. Nuvama maintained a ‘Hold’ rating, citing competition risks and potential U.S. policy headwinds. ...Less

Analysts believe the performance will give a boost to shares of the company that have seen undeserving se ...More

Analysts believe the performance will give a boost to shares of the company that have seen undeserving selling. ...Less

Sun Pharma shares traded 2.78 per cent higher at Rs 482.25 after the announcement of its quarterly result ...More

Sun Pharma shares traded 2.78 per cent higher at Rs 482.25 after the announcement of its quarterly results. ...Less

“Sun Pharma expects to gain momentum and continue to focus on building the prescriptions for core special ...More

“Sun Pharma expects to gain momentum and continue to focus on building the prescriptions for core specialty products.” ...Less

Sun Pharmaceuticals and Maruti Suzuki India are among the companies declaring their Q3FY24 earnings. Maru ...More

Sun Pharmaceuticals and Maruti Suzuki India are among the companies declaring their Q3FY24 earnings. Maruti Suzuki India is expected to report healthy revenue growth, while Sun Pharmaceuticals may see moderate revenue growth. ...Less

The earnings before interest, tax, depreciation and ammortisation (EBITDA) grew 15.2% YoY to Rs. 3004 cro ...More

The earnings before interest, tax, depreciation and ammortisation (EBITDA) grew 15.2% YoY to Rs. 3004 crore. The EBITDA margin for Q3FY23 improved 30 basis points YoY to 26.7%.Global specialty drug sales were at $235 million, including US$12.5 million milestone received in Q3FY23. Ex-milestone, the specialty sales were up 21.6% YoY in Q3FY23. ...Less

Prabhudas Lilladher expects Sun Pharma to report a 7.1 per cent increase in net profit from a year ago, w ...More

Prabhudas Lilladher expects Sun Pharma to report a 7.1 per cent increase in net profit from a year ago, while it believes net sales may have slipped 0.2 per cent. ...Less

The company said during the quarter and year ended March 31, 2022 the company incurred a one-time cost of ...More

The company said during the quarter and year ended March 31, 2022 the company incurred a one-time cost of Rs 56.35 crore in relation to restructuring of operations In certain countries, this has been disclosed as an exceptional item. The company also provided Rs 156.25 crore for a settlement of lawsuit in the US. ...Less

The drugmaker reported a 12.5 per cent YoY rise in its consolidated revenue from operations to Rs 9,625.9 ...More

The drugmaker reported a 12.5 per cent YoY rise in its consolidated revenue from operations to Rs 9,625.9 crore for the reported quarter, which was also above Street’s estimate. ...Less

Sun Pharma reported a 28% year-on-year (YoY) jump in net profit to Rs 3040 crore in Q2FY25 led by higher ...More

Sun Pharma reported a 28% year-on-year (YoY) jump in net profit to Rs 3040 crore in Q2FY25 led by higher sales growth in domestic formulation and global specialty portfolio. ...Less

Sun Pharma Q1FY24 net profit fell 2% YoY to Rs 2023 crore due to exceptional items worth Rs 323 crore. Ho ...More

Sun Pharma Q1FY24 net profit fell 2% YoY to Rs 2023 crore due to exceptional items worth Rs 323 crore. However, excluding exceptional items, net profit for Q1FY24 grew 13.8% to Rs 2345 crore. Earnings for interest, tax, depreciation, and ammortisation (EBITDA) grew 15.5% to Rs 3332 crore in Q1. ...Less

Sun Pharma Share Price: Sun Pharmaceuticals' shares fell by 2% despite a strong financial performance in ...More

Sun Pharma Share Price: Sun Pharmaceuticals' shares fell by 2% despite a strong financial performance in the second quarter. The company reported a 28% increase in net profit to Rs 3,040 crore. Analysts have mixed views; Jefferies has a 'Buy' rating, while Goldman Sachs maintains a 'Sell' rating, with concerns about upcoming higher R&D expenses and launch costs. ...Less

The fall in the bottomline was partly due to certain one-time charges totalling Rs 323 crore. The company ...More

The fall in the bottomline was partly due to certain one-time charges totalling Rs 323 crore. The company also incurred a one-time transitional cost of Rs 51 crore on the relocation of Alchemee operations from California to New York. ...Less

Sun Pharma Q3 Results: The company has also declared an interim dividend of Rs 10.5 per share for the fin ...More

Sun Pharma Q3 Results: The company has also declared an interim dividend of Rs 10.5 per share for the financial year 2024-25. ...Less

Total revenue for the quarter grew 10.73 per cent YoY to Rs 10,761.76 crore compared with Rs 9,718.74 cro ...More

Total revenue for the quarter grew 10.73 per cent YoY to Rs 10,761.76 crore compared with Rs 9,718.74 crore in the corresponding quarter last year. The revenue also beat the ET NOW poll projection of Rs 10,425 crore. ...Less

The total revenue from operations came in at Rs 9,863.06 crore, up 11.61 per cent against Rs 8,836.78 cro ...More

The total revenue from operations came in at Rs 9,863.06 crore, up 11.61 per cent against Rs 8,836.78 crore in the corresponding quarter last year. ...Less

Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, s ...More

Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales. ...Less

Sun Pharma Q4 Results: The company's revenue rose 10% year-on-year to Rs 11,983 crore in the reporting qu ...More

Sun Pharma Q4 Results: The company's revenue rose 10% year-on-year to Rs 11,983 crore in the reporting quarter. It was Rs 10,931 crore a year ago. Its board has approved a final dividend of Rs 5 per share, which will be paid within the prescribed timeline. India formulations sales were Rs 3,707 crore for the fourth quarter, showing growth of 10% over Q4 last year and accounted for 31.4% of total consolidated sales for the quarter. ...Less

Today, 173 companies will disclose their Q2 earnings, including Airtel, Sun Pharma, and Adani Power. Bhar ...More

Today, 173 companies will disclose their Q2 earnings, including Airtel, Sun Pharma, and Adani Power. Bharti Airtel is anticipated to post robust performance with significant net profit growth, while Sun Pharma is expected to see healthy revenue growth driven by its domestic operations and specialty sales in the US market. ...Less

Sun Pharma Q1 Results FY26: Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net prof ...More

Sun Pharma Q1 Results FY26: Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net profit, reaching Rs 2,278 crore. Despite this dip, revenue from operations increased by 10% to Rs 13,786 crore. Strong performance in the India market and growth in global innovative medicines sales, including the U.S. launch of LEQSELVI, contributed to the company's overall progress. ...Less

Bharti Airtel Q2 Results: The company's revenue from operations for the quarter reached Rs 41,473 crore, ...More

Bharti Airtel Q2 Results: The company's revenue from operations for the quarter reached Rs 41,473 crore, marking a 12% increase from Rs 37,044 crore in the same quarter last year. The average revenue per user (ARPU) rose 15% year-on-year to Rs 233 from Rs 203 in Q2FY24. Consolidated net income (before exceptional items) increased by 32.2% YoY to Rs 3,911 crore. ...Less

Adani Enterprises Q1 Results FY26: Adani Enterprises experienced a 45% profit drop in the first quarter, ...More

Adani Enterprises Q1 Results FY26: Adani Enterprises experienced a 45% profit drop in the first quarter, reaching Rs 976.48 crore. Revenue also decreased by 13.7% to Rs 21,961.20 crore. Lower trade volumes and index price volatility impacted performance. However, incubating businesses saw a 5% EBITDA increase, driven by Airports and Roads segments. Navi Mumbai Airport and other projects are expected to contribute to future EBITDA. ...Less

Revenue from operations during the quarter rose 14% to Rs 11,240 crore against Rs 9,863 crore in the corr ...More

Revenue from operations during the quarter rose 14% to Rs 11,240 crore against Rs 9,863 crore in the corresponding quarter of the previous year. ...Less

Nomura maintains a buy rating on Macrotech Developers with a target price of Rs 1,600, citing strong Q2 p ...More

Nomura maintains a buy rating on Macrotech Developers with a target price of Rs 1,600, citing strong Q2 performance and anticipated 20% YoY pre-sales growth. For BPCL, Nomura raises the target to Rs 380 despite lower results. Nuvama and Jefferies also maintain buy ratings on Federal Bank (target Rs 235) and Sun Pharma (target Rs 2,150), respectively, highlighting strong performance and growth potential. ...Less

Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consol ...More

Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consolidated revenue grew 10% YoY. The company recommended an interim dividend payout. EBITDA rose 16% YoY and margins expanded. Raw material cost fell, but staff cost increased. India formulation sales and US formulation sales grew, while emerging markets formulation sales declined. ...Less

The big miss on the bottomline by the company was a result of an exceptional loss worth Rs 672.8 crore re ...More

The big miss on the bottomline by the company was a result of an exceptional loss worth Rs 672.8 crore related to various litigation settlements pertaining to some of its subsidiaries. ...Less

Sun Pharma reported a 19% YoY drop in Q4FY25 net profit to Rs 2,154 crore, while revenue rose 8% to Rs 12 ...More

Sun Pharma reported a 19% YoY drop in Q4FY25 net profit to Rs 2,154 crore, while revenue rose 8% to Rs 12,959 crore. Final dividend set at Rs 5.50/share. ...Less

The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the N ...More

The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price. ...Less

ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun ...More

ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC's revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma. ...Less

The S&P BSE Sensex rallied as much as 355 points in intraday trade on Tuesday led by gains in auto, capit ...More

The S&P BSE Sensex rallied as much as 355 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less

"Investors will continue to watch global developments before committing more money to equities," as per a ...More

"Investors will continue to watch global developments before committing more money to equities," as per an IIFL report. ...Less

The S&P BSE Sensex rallied nearly 400 points in intraday trade on Tuesday led by gains in auto, capital g ...More

The S&P BSE Sensex rallied nearly 400 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less

The S&P BSE Sensex rallied as much as 266 points in intraday trade on Tuesday led by gains in auto, capit ...More

The S&P BSE Sensex rallied as much as 266 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less

For the full year, Sun notched up net sales/total income of Rs 27744 crore, growing 2% over the correspon ...More

For the full year, Sun notched up net sales/total income of Rs 27744 crore, growing 2% over the corresponding year last year. ...Less